Brief: Adaptive Biotechnologies Receives Expanded Medicare Coverage Of Clonoseq For Assessing Measurable Residual Disease In Mantle Cell Lymphoma
07/11/2024 12:57
Nov 7 (Reuters) - Adaptive Biotechnologies Corp
ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES RECEIVES EXPANDED MEDICARE
COVERAGE OF
CLONOSEQ® FOR ASSESSING MEASURABLE RESIDUAL DISEASE IN MANTLE
CELL LYMPHOMA
Source text: ID:nGNX7qpZg0
Further company coverage: ADPT.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Adaptive Biotechnologies
See all newsAdvisory: Alert incorrectly tagged to Adaptive Biotechnologies withdrawn
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary
Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates